1. Home
  2. EDBL vs HCWB Comparison

EDBL vs HCWB Comparison

Compare EDBL & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Edible Garden AG Incorporated

EDBL

Edible Garden AG Incorporated

HOLD

Current Price

$0.53

Market Cap

3.6M

ML Signal

HOLD

Logo HCW Biologics Inc.

HCWB

HCW Biologics Inc.

HOLD

Current Price

$1.31

Market Cap

3.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EDBL
HCWB
Founded
2020
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Farming/Seeds/Milling
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.6M
3.8M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
EDBL
HCWB
Price
$0.53
$1.31
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$35.00
AVG Volume (30 Days)
3.0M
83.5K
Earning Date
11-14-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$12,553,000.00
$422,026.00
Revenue This Year
$29.56
$178.64
Revenue Next Year
$20.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.48
$0.95
52 Week High
$7.75
$41.20

Technical Indicators

Market Signals
Indicator
EDBL
HCWB
Relative Strength Index (RSI) 35.46 42.63
Support Level $0.56 $1.19
Resistance Level $1.24 $1.65
Average True Range (ATR) 0.11 0.14
MACD 0.00 0.05
Stochastic Oscillator 2.41 34.55

Price Performance

Historical Comparison
EDBL
HCWB

About EDBL Edible Garden AG Incorporated

Edible Garden AG Inc is a next-generation controlled environment agriculture farming company. It uses traditional agricultural growing techniques together with technology to grow fresh, organic food, sustainably and safely while improving traceability. The company uses the controlled environment of traditional greenhouse structures, such as glass greenhouses together with hydroponic and vertical greenhouses to sustainably grow organic herbs and lettuces.

About HCWB HCW Biologics Inc.

HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.

Share on Social Networks: